QuidelOrtho Corp

QDELNasdaq· In Vitro & In Vivo Diagnostic Substances

Price History

Revenue

$2.7B

▼ 1.9% YoY

Net Income

-$1.1B

▲ 44.8% YoY

EPS

$-16.69

▲ 45.4% YoY

Cash

$169.8M

▲ 72.7% YoY

FY 2025 · As of 2025-12-28

Pro

10-K Year-over-Year Diff

AI-powered analysis of what changed between the last two annual reports — new risks, removed language, strategy shifts.